title: [Functional assessment of nigro-striatal pathway with FP-CIT in patients with multiple system atrophy subtype C].
abstract: OBJECTIVE
  To assess the functional state of nigro-striatal pathway using FP-CIT-I-123 in patients with clinical diagnosis of Multiple System Atrophy (MSA) subtype C.
  
  
  METHODS
  We included 10 patients with a clinical diagnosis of MSA-C and compared them with 10 patients diagnosed with essential tremor (controls) and 10 with Parkinson Disease (PD). The studies are evaluated by the striatum/occipital index (S/O). We calculated the diagnostic validity of the procedure by ROC curve analysis.
  
  
  RESULTS
  The average value of the S/O index showed a mean of 1.48 (0.23), 1.59 (0.17) and 1.22 (0.16) respectively for MSA-C, control group (p=0.25) and PD (p=0.00). ROC curve analysis: Az: 0.650; sensitivity: 0.50; specificity: 0.80. The comparison between the results of FP-CIT and clinical manifestations showed: 4 patients with parkinsonism (PK) and pathological study; 4 without PK and normal study; 1 with PK and normal study and 1 without PK and pathological study.
  
  
  CONCLUSIONS
  FP-CIT study does not exclude completely the existence of an MSA-C. From a functional point of view, there does not always seem to be a consistency between the state of the nigro-striatal pathway and the existence of parkinsonism.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Martínez del Valle Torres
authors.forename: Esperanza
authors.initials: E
authors.lastname: Ramos Moreno
authors.forename: Tomader
authors.initials: T
authors.lastname: Amrani Raissouni
authors.forename: Simeón J
authors.initials: SJ
authors.lastname: Ortega Lozano
authors.forename: Salomé
authors.initials: S
authors.lastname: Sanz Viedma
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Jiménez-Hoyuela
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D002531:Cerebellum / Q000503:physiopathology; D003342:Corpus Striatum / Q000737:chemistry / Q000000981:diagnostic imaging*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000032:analysis*; D020329:Essential Tremor / Q000000981:diagnostic imaging; D005260:Female; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000145:classification / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000032:analysis; D010300:Parkinson Disease / Q000000981:diagnostic imaging; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging* / Q000209:etiology; D012372:ROC Curve; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015899:Tomography, Emission-Computed, Single-Photon; D014326:Tropanes / Q000493:pharmacokinetics
chemical_list: D002250:Carbon Radioisotopes; D050483:Dopamine Plasma Membrane Transport Proteins; D005462:Fluorine Radioisotopes; D007457:Iodine Radioisotopes; D009419:Nerve Tissue Proteins; D019275:Radiopharmaceuticals; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane